Develops RNA editing medicines for rare and prevalent diseases.
Jun 2026Revenue $2.38M/yrExpenses $113M/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will Korro Bio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $2.38M and expenses $113M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $6.39M | $128M | −$122M |
| Dec 2024 | $2.27M | $94.2M | −$91.9M |
| Dec 2023 | $0.00 | $84.5M | −$84.5M |
| Dec 2022 | $0.00 | $59.0M | −$59.0M |
| Dec 2021 | $14.1M | $98.1M | −$84.0M |
| Dec 2020 | $37.0M | $64.5M | −$27.6M |
| Dec 2019 | $28.9M | $49.6M | −$20.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.